Mary Kate (for Geoff Porges)'s questions to Kiniksa Pharmaceuticals International PLC (KNSA) leadership • Q1 2025
Question
Mary Kate, on behalf of Geoff Porges, inquired about the factors driving the increased duration of ARCALYST therapy and the patient experience feedback received.
Answer
Chief Commercial Officer Ross Moat attributed the longer duration to a growing physician understanding of recurrent pericarditis as a multiyear disease and high patient willingness to remain on an effective therapy. He noted that patient services via Kiniksa One Connect receive positive feedback, supporting adherence and the overall patient journey.